Alan Carson Selected Research

Seizures (Absence Seizure)

1/2021	Cognitive-behavioural therapy compared with standardised medical care for adults with dissociative non-epileptic seizures: the CODES RCT.
1/2020	Cognitive behavioural therapy for adults with dissociative seizures (CODES): a pragmatic, multicentre, randomised controlled trial.
11/2019	Characteristics of 698 patients with dissociative seizures: A UK multicenter study.
1/2017	COgnitive behavioural therapy versus standardised medical care for adults with Dissociative non-Epileptic Seizures (CODES): statistical and economic analysis plan for a randomised controlled trial.
6/2015	COgnitive behavioural therapy vs standardised medical care for adults with Dissociative non-Epileptic Seizures (CODES): a multicentre randomised controlled trial protocol.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Alan Carson Research Topics

Disease

5	Psychogenic Nonepileptic Seizures 03/2022 - 11/2019
5	Conversion Disorder (Astasia Abasia) 11/2021 - 04/2015
5	Seizures (Absence Seizure) 01/2021 - 06/2015
2	Epilepsy (Aura) 01/2021 - 11/2019
2	Glioma (Gliomas) 01/2013 - 11/2011
1	COVID-19 02/2024
1	Craniocerebral Trauma (Head Injury) 01/2023
1	Pain (Aches) 01/2023
1	Brain Injuries (Brain Injury) 01/2023
1	Cognitive Dysfunction 12/2021
1	Dyskinesias (Dyskinesia) 10/2021
1	Cough 10/2021
1	Delirium 01/2021
1	Brain Diseases (Brain Disorder) 01/2021
1	Stroke (Strokes) 10/2020
1	Medically Unexplained Symptoms 01/2020
1	Chorea (Rheumatic Chorea) 01/2019
1	Mental Disorders (Mental Disorder) 01/2019
1	Movement Disorders (Movement Disorder) 01/2019
1	Tardive Dyskinesia 01/2019
1	Psychomotor Agitation (Akathisia) 11/2018
1	Motor Disorders 10/2016
1	Neurobehavioral Manifestations 02/2016
1	Chronic Pain 01/2016

Drug/Important Bio-Agent (IBA)

2	BenzodiazepinesIBA 01/2023 - 11/2018
2	Opiate AlkaloidsIBA 01/2023 - 01/2016
2	Antipsychotic Agents (Antipsychotics)IBA 01/2019 - 11/2018
1	mesoglycanIBA 02/2024
1	Biomarkers (Surrogate Marker)IBA 01/2023
1	Riluzole FDA LinkGeneric 12/2021
1	COVID-19 VaccinesIBA 11/2021
1	insulin receptor-related receptor (IRR)IBA 01/2020
1	Sodium Glutamate (Accent)IBA 11/2019
1	Quetiapine Fumarate (Seroquel)FDA Link 01/2019
1	Clozapine (Clozaril)FDA LinkGeneric 01/2019
1	valbenazineIBA 01/2019
1	deutetrabenazineIBA 01/2019
1	Cholinergic Antagonists (Anticholinergics)IBA 11/2018
1	Vitamin B 6IBA 11/2018
1	Cholinesterase Inhibitors (Anticholinesterases)IBA 02/2016
1	2'- deoxythymidylyl- (3'- 5')- 2'- deoxyadenosine (d(AT))IBA 01/2013

Therapy/Procedure

9	Therapeutics 03/2022 - 04/2015
2	Critical Care (Surgical Intensive Care) 01/2021 - 10/2020
1	Language Therapy (Language Training) 10/2021
1	Duration of Therapy 01/2019
1	Drug Tapering 11/2018
1	Polypharmacy 11/2018
1	Occupational Therapy (Therapy, Occupational) 01/2018
1	Transcranial Magnetic Stimulation 10/2016
1	Physical Therapy Modalities (Physical Therapy Technique) 06/2015
1	Radiotherapy 11/2011